PLIVA d.d. announced today that an agreement has been signed with Novartis’ generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L for a total cash consideration of EUR 21.5m.

PLIVA d.d. (LSE: PLVD) today announced a deal in which it has reached agreement with GlaxoSmithKline (GSK) for the purchase of PLIVA – Istraživački Institut d.o.o. (PLIVA – Research Institute Ltd.), PLIVA’s proprietary R&D arm renowned for its research into macrolides, in Zagreb, Croatia. In May 2005, PLIVA announced its strategic intent to completely focus on its generics operations and exit the proprietary business. Following the divestments of the majority of PLIVA’s US proprietary business and Research Institute in Zagreb, PLIVA has now successfully completed its strategic objective of exiting the proprietary segment.

PLIVA d.d. announced today that its German subsidiary AWD.pharma GmbH & Co. KG signed an agreement with the Menarini Group (“Menarini”) of Italy, for the divestment of its manufacturing plant in Dresden, Germany. The sale of the German facility reflects a key step in the process of optimizing PLIVA’s manufacturing asset base and consolidation of production, which was announced at the end of 2004.

PLIVA d.d. announced today that following an in-depth strategic review and evaluation of its core activities and approval from its Supervisory Board, it has decided to exit the proprietary segment and focus operations on its generics business.

Please find PLIVA's Q1 Results attached in pdf format.

PLIVA d.d. announced today that its affiliates PAM Kft. and PLIVA CROATIA Ltd. have entered into a strategic collaboration with Mayne Pharma, a leading international hospital generics company, for the development, supply and marketing of PLIVA’s two most advanced followon biologics programs, erythropoietin (EPO) and granulocyte colony stimulating factor (“G-CSF”).

H1 2004 Results announced.

PLIVA-Lachema is pleased to announce that the US regulatory authority for pharmaceuticals - the Food and Drug Administration (FDA) - has classified the facility as acceptable for the production of Active Pharmaceutical Ingredients and Sterile Dosage Forms – Carboplatin and Dacarbazine injections for the American market in Brno, Czech Republic. PLIVA-Lachema has thus become the first company in the Czech Republic approved by the FDA in the field of sterile dosage form manufacture.

PLIVA-Lachema has ceremonially opened a Pilot Plant for the active cytostatic pharmaceutical substances in the presence of Zdeněk Škromach, Czech Minister of Labor and Social Affairs.

“I am proud to announce that the year 2003 marked a milestone in PLIVA's history as, for the first time ever, revenues surpassed USD 1 billion. However, this also was a year of challenge as we consolidated and integrated our network following several years of acquisitions. The result of this is the New PLIVA organizational structure, in effect as of January 2004. The new structure will enable us to become more functional and lean and to maximize synergies across PLIVA companies. This was necessary because PLIVA has become a global company with over 80% of its revenues derived outside Croatia. Furthermore, we have decreased our traditional reliance on our CEE roots as today Western Europe and North America together represent the main contributors to sales. Lastly, I would like to stress that, in the quest for the continuous enhancement of our performance and increasing profitability, both in 2004 and the future, we remain committed to further rationalization of our cost structure and refinement of our business model."

Željko Čović, PLIVA's CEO and President of the Management Board of PLIVA d.d.